n(6)-carboxymethyllysine has been researched along with Hip Fractures in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alfonso, H; Almeida, OP; Davis, TME; Flicker, L; Forbes, J; Golledge, J; Hankey, GJ; Irrgang, F; Lamb, LS; Müench, G; Norman, PE; Yeap, BB | 1 |
| Barzilay, JI; Bůžková, P; Cauley, JA; Djoussé, L; Ix, JH; Kizer, JR; Mukamal, KJ; Siscovick, DS; Tracy, RP; Zieman, SJ | 1 |
2 other study(ies) available for n(6)-carboxymethyllysine and Hip Fractures
| Article | Year |
|---|---|
Advanced Glycation End Products and esRAGE Are Associated With Bone Turnover and Incidence of Hip Fracture in Older Men.
Topics: Age Factors; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Bone Density; Bone Remodeling; Diabetes Mellitus; Follow-Up Studies; Glycation End Products, Advanced; Hip Fractures; Humans; Incidence; Lysine; Male; Predictive Value of Tests; Prognosis; Pyruvaldehyde; Receptor for Advanced Glycation End Products; Risk Factors | 2018 |
Circulating levels of carboxy‐methyl‐lysine (CML) are associated with hip fracture risk: the Cardiovascular Health Study.
Topics: Age Factors; Aged; Female; Follow-Up Studies; Glycation End Products, Advanced; Hip Fractures; Humans; Incidence; Lysine; Male; Prospective Studies; Retrospective Studies; Risk Factors | 2014 |